-
Je něco špatně v tomto záznamu ?
Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases
V. Treska, O. Topolcan, V. Zoubkova, I. Treskova, A. Narsanska, R. Kucera,
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
Open Access Digital Library
od 2004-01-01
- MeSH
- analýza přežití MeSH
- antigen CA-19-9 krev MeSH
- antigeny nádorové krev MeSH
- dospělí MeSH
- karcinoembryonální antigen krev MeSH
- keratin-19 krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory jater sekundární chirurgie MeSH
- nádory prsu patologie chirurgie MeSH
- peptidy krev MeSH
- perioperační období * MeSH
- prognóza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: The results of surgical treatment of breast cancer liver metastases (BCLM) remain suboptimal. The search for perioperative prognostic factors could help determine high risk groups of patients. The aim of study was to evaluate the significance of tumour markers (TM) on long-term treatment results. PATIENTS AND METHODS: Liver surgery was carried out in 32 women for BCLM. The perioperative serum levels of CEA, CA19-9, TPA, TPS, CYFRA 21-1 and TK were determined. RESULTS: Preoperative levels of CA19-9 were significant for overall survival (OS)(p<0.05) and recurrence-free survival (RFS) (p<0.01). TPA, TPS and CYFRA 21-1 levels were significant for OS (p<0.05; p<0.04; p<0.05). Postoperative levels of CEA, TPS and CYFRA 21-1 were significant for RFS (p<0.04; p<0.01; p<0.02), while CA19-9 postoperative levels were significant for OS and RFS (p<0.03; p<0.01). CONCLUSION: Perioperative TM serum levels may represent prognostic indicators reflecting the results of surgical treatment of BCLM.
Department of Surgery University Hospital Faculty of Medicine Pilsen Czech Republic
Immunodiagnostic Department University Hospital Faculty of Medicine Pilsen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024211
- 003
- CZ-PrNML
- 005
- 20190730090748.0
- 007
- ta
- 008
- 180709s2018 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.12640 $2 doi
- 035 __
- $a (PubMed)29848722
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Treska, Vladislav $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic treska@fnplzen.cz.
- 245 10
- $a Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases / $c V. Treska, O. Topolcan, V. Zoubkova, I. Treskova, A. Narsanska, R. Kucera,
- 520 9_
- $a BACKGROUND/AIM: The results of surgical treatment of breast cancer liver metastases (BCLM) remain suboptimal. The search for perioperative prognostic factors could help determine high risk groups of patients. The aim of study was to evaluate the significance of tumour markers (TM) on long-term treatment results. PATIENTS AND METHODS: Liver surgery was carried out in 32 women for BCLM. The perioperative serum levels of CEA, CA19-9, TPA, TPS, CYFRA 21-1 and TK were determined. RESULTS: Preoperative levels of CA19-9 were significant for overall survival (OS)(p<0.05) and recurrence-free survival (RFS) (p<0.01). TPA, TPS and CYFRA 21-1 levels were significant for OS (p<0.05; p<0.04; p<0.05). Postoperative levels of CEA, TPS and CYFRA 21-1 were significant for RFS (p<0.04; p<0.01; p<0.02), while CA19-9 postoperative levels were significant for OS and RFS (p<0.03; p<0.01). CONCLUSION: Perioperative TM serum levels may represent prognostic indicators reflecting the results of surgical treatment of BCLM.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antigeny nádorové $x krev $7 D000951
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a nádory prsu $x patologie $x chirurgie $7 D001943
- 650 _2
- $a antigen CA-19-9 $x krev $7 D018395
- 650 _2
- $a karcinoembryonální antigen $x krev $7 D002272
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a keratin-19 $x krev $7 D053539
- 650 _2
- $a nádory jater $x sekundární $x chirurgie $7 D008113
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a peptidy $x krev $7 D010455
- 650 12
- $a perioperační období $7 D059035
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Topolcan, Ondrej $u Immunodiagnostic Department, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Zoubková, Věra $7 xx0238427 $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Treskova, Inka $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Narsanska, Andrea $u Department of Surgery, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 700 1_
- $a Kucera, Radek $u Immunodiagnostic Department, University Hospital, Faculty of Medicine, Pilsen, Czech Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 6 (2018), s. 3647-3652
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29848722 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20190730090951 $b ABA008
- 999 __
- $a ok $b bmc $g 1316342 $s 1021132
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 38 $c 6 $d 3647-3652 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20180709
